Rituximab Intravenous Products Clinical Resource
Customize your policy alerts
Sign up for all quartz policy alerts
Know when quartz releases new policies or updates existing guidance.
Monitor payer policy activity
Governs Quartz coverage, clinical guidance, dosing, and prior authorization requirements for rituximab intravenous products (brand and biosimilars) across approved indications for affected members and providers.
No material clinical or coverage changes in this revision.
Coverage Criteria and Indication-Specific Requirements
Covered indications with criteria
Covered when ALL of the following are met (per indication):
General Dosing Options
Covered when ALL of the following dosing options are met for listed hematology/oncology indications:
General dosing patterns (policy dosing section).
Multiple Sclerosis — Initial or Repeat Courses
Covered for Multiple Sclerosis when ALL of the following are met:
Dosing: up to 2,000 mg total administered as one or two IV infusions over 1 month.
Neuromyelitis Optica Spectrum Disorder — Dosing
Covered for Neuromyelitis Optica Spectrum Disorder when dosing matches one of the following:
(policy dosing section).
Primary Central Nervous System Lymphoma — Dosing
Covered for Primary Central Nervous System Lymphoma when dosing is:
(policy dosing section).
Systemic Lupus Erythematosus — Use Conditions
Covered for SLE when ALL of the following are met:
(policy guidance).
Waldenstrom's Macroglobulinemia/LPL — Dosing
Covered for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma when dosing is:
(policy dosing section).
Requests for the brand product Rituxan require evaluation of medical necessity and are not covered without review. Rituxan Hycela (rituximab/hyaluronidase subcutaneous) has only been evaluated following at least one full IV rituximab dose for certain lymphomas and CLL, has not been evaluated for non-malignant conditions, and is not interchangeable with other rituximab products.
Use of rituximab is not recommended in clinical circumstances where supporting data are lacking; such indications should not be approved when evidence does not support benefit.
The brand product Rituxan requires a prior medical necessity review and is not covered without approval. Biosimilar rituximab products have demonstrated biosimilarity but brand Rituxan still requires evaluation of medical necessity prior to use.
Indications for rituximab that lack adequate supporting clinical data are considered not recommended for approval and are treated as not medically necessary in the absence of evidence of benefit.
Provider Requirements, Prior Authorization, and Documentation
Prior authorization: biosimilars vs. brand Rituxan
Rituximab biosimilar products (e.g., Riabni, Ruxience, Truxima) do not require prior authorization. In contrast, requests for BRAND Rituxan require a medical necessity review and are not covered without approval; Medicare Advantage requests may also be subject to NCDs/LCDs.
Prior authorization: verify prerequisite therapies and intervals
Prior authorization reviews must verify that required prior therapies and minimum intervals are met for the requested indication (examples below include MS and SLE).
- Multiple sclerosis: documentation of inadequate response or intolerance to at least TWO other disease‑modifying agents and that rituximab will not be used concurrently with another MS DMT; confirm at least 6 months between courses when repeating therapy.
- Systemic lupus erythematosus: documentation of trial of at least ONE standard immunomodulating or immunosuppressant agent; for repeat courses, confirm 6 months or greater between course start dates.
Step therapy prerequisites (general)
For some indications the policy requires documented prior trials before initiating rituximab (step therapy).
- Rheumatoid arthritis: trial of ONE conventional synthetic DMARD for ≥3 months prior to rituximab.
- Immune thrombocytopenia (ITP): trial of one other therapy such as IVIG, anti‑D immunoglobulin, corticosteroids, or splenectomy prior to rituximab.
- Multiple sclerosis: inadequate response or intolerance to at least TWO other DMTs prior to rituximab.
Step therapy specifics for MS and SLE
Certain indications specify exact step therapy or failure/intolerance requirements and minimum timing between courses.
- MS: failure or intolerance to ≥2 other disease‑modifying therapies and at least 6 months between courses.
- SLE: trial of ≥1 standard immunomodulating or immunosuppressant agent; if repeating a course, ensure ≥6 months between course start dates.
Required prescriber specialty and consultations
Prescriber specialty must be documented for certain indications and prescriber consultation/monitoring is required for others.
- Rheumatoid arthritis: prescribed by or in consultation with a rheumatologist.
- Pemphigus vulgaris: prescribed by or in consultation with a dermatologist; dermatologist should monitor relapse/maintenance.
- ANCA‑associated vasculitis: prescribed by or in consultation with a rheumatologist, nephrologist, or immunologist.
- Immune‑related toxicities: prescribed by or in consultation with an oncologist, neurologist, rheumatologist, or dermatologist.
Prior therapy, response, and timing documentation required
Authorization requests must include documentation of prior therapy use, outcomes, and dates to confirm required timing between courses where specified.
- Document prior use and intolerance or inadequate response to required therapies (e.g., ≥2 DMTs for MS; ≥1 immunomodulating agent for SLE).
- When repeating a rituximab course, provide dates of prior rituximab doses to confirm minimum intervals (e.g., ≥6 months between course start dates for MS and SLE; ≥16 weeks for some maintenance uses).
- For ITP, document prior response to the previous rituximab course and evidence of relapse if proposing retreatment after ≥6 months.
Brand Rituxan requires medical necessity review
Requests for brand Rituxan will be evaluated for medical necessity prior to approval; brand Rituxan is not covered without this review and may be denied if criteria are not met.
Not recommended uses — insufficient evidence
Use of rituximab is not recommended where clinical data do not support its use; such indications are not recommended for approval.
- Conditions explicitly listed under 'Conditions Not Recommended for Approval' should not be approved because evidence does not support rituximab use.
Dosing Regimens and Administration Schedules
| Indication | Regimen / Dosing (IV) | Coverage status |
|---|---|---|
| Non-Hodgkin lymphoma and other B-cell lymphomas (e.g., follicular, DLBCL, mantle cell, marginal zone, Burkitt, primary mediastinal, primary cutaneous, post-transplant lymphoproliferative disorders, pediatric aggressive mature B-cell) | ||
| Rituximab combined with first-line chemotherapy (e.g., CHOP or other anthracycline-based regimens) or as single-agent maintenance after response. Dosing examples: 375 mg/m2 IV per dose with doses separated by ≥7 days, OR 375 mg/m2 IV on two days of each cycle. |
| Indication | Regimen / Dosing (IV) | Coverage status |
|---|---|---|
| Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) in combination with fludarabine and cyclophosphamide (FC) | ||
| Use up to 500 mg/m2 administered as an intravenous infusion on 1 day of each cycle. |
| Indication or Context | Regimen / Dosing (IV) | Coverage status |
|---|---|---|
| Oncology common dosing (various hematologic malignancies) | ||
| 375 mg/m2 IV per dose with doses separated by ≥7 days; alternative oncology option: 500 mg/m2 IV x2 doses separated by ≥14 days. | ||
| Neuromyelitis optica spectrum disorder (NMOSD) | ||
| Up to two 1000 mg IV doses separated by ≥2 weeks. | ||
| Multiple sclerosis (MS) — per-course total dosing | ||
| Up to 2,000 mg total administered as one or two IV infusions over 1 month. |
Line of Therapy and Positioning
first-line
not_specified
Definitions and Biomarker/Other Requirements
Clinical Background
Rituximab products are CD20-directed cytolytic antibodies that deplete CD20-expressing B cells and are used across a range of hematologic malignancies and immune-mediated disorders. Approved IV indications include multiple B‑cell malignancies (for example, various non‑Hodgkin lymphomas and chronic lymphocytic leukemia) as well as selected autoimmune diseases such as rheumatoid arthritis and pemphigus vulgaris; rituximab subcutaneous formulation (Rituxan Hycela) is indicated only after at least one full IV dose for certain lymphomas/CLL and has not been evaluated for non‑malignant conditions.
Policy Revision History
Last review and policy effective date — clinical resource for rituximab IV products updated and confirmed current.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.